{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:52:11Z","timestamp":1793962331743,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.gore.2024.101383","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T07:48:45Z","timestamp":1712476125000},"page":"101383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Maximizing ovarian function and fertility following chemotherapy in premenopausal patients: Is there a role for ovarian suppression?"],"prefix":"10.1016","volume":"53","author":[{"given":"Kelsey A.","family":"Roof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri E.","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Modesitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Austin","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2024.101383_b0005","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/160386","article-title":"Fertility preservation for cancer patients: a review","volume":"2010","author":"Ajala","year":"2010","journal-title":"Obstet. Gynecol. Int."},{"issue":"6","key":"10.1016\/j.gore.2024.101383_b0010","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/humrep\/des101","article-title":"The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments","volume":"27","author":"Anckaert","year":"2012","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.gore.2024.101383_b0015","article-title":"Burning questions in the oncofertility counseling of young breast cancer patients","volume":"14","author":"Arecco","year":"2020","journal-title":"Breast Cancer (Auckl.)"},{"issue":"1","key":"10.1016\/j.gore.2024.101383_b0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09513590.2020.1753033","article-title":"An assessment of the protective effect of gonadotropin-releasing hormone agonist and antagonist on bleomycin-induced ovarian toxicity in rats","volume":"37","author":"Atakul","year":"2021","journal-title":"Gynecol. Endocrinol."},{"issue":"20","key":"10.1016\/j.gore.2024.101383_b0025","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2217\/fon-2016-0176","article-title":"Chemotherapy-induced damage to ovary: mechanisms and clinical impact","volume":"12","author":"Bedoschi","year":"2016","journal-title":"Future Oncol."},{"key":"10.1016\/j.gore.2024.101383_b0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7827-8-20","article-title":"Doxorubicin-induced ovarian toxicity","volume":"8","author":"Ben-Aharon","year":"2010","journal-title":"Reprod. Biol. Endocrinol."},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/REP-12-0121","article-title":"What lies behind chemotherapy-induced ovarian toxicity?","volume":"144","author":"Ben-Aharon","year":"2012","journal-title":"Reproduction"},{"issue":"4","key":"10.1016\/j.gore.2024.101383_b0040","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1095\/biolreprod63.4.1106","article-title":"Expression and tissue concentration of vascular endothelial growth factor, its receptors, and localization in the bovine corpus luteum during estrous cycle and pregnancy","volume":"63","author":"Berisha","year":"2000","journal-title":"Biol. Reprod."},{"issue":"3","key":"10.1016\/j.gore.2024.101383_b0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2005.04.5393","article-title":"Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients\u2013the international breast cancer study group trial VIII","volume":"25","author":"Bernhard","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.gore.2024.101383_b0050","first-page":"2912","article-title":"GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro","volume":"30","author":"Bildik","year":"2015","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.gore.2024.101383_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.690320","article-title":"The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and\/or fertility preservation strategies in premenopausal women with early breast cancer","volume":"11","author":"Blondeaux","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.gore.2024.101383_b0060","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1634\/theoncologist.12-9-1044","article-title":"How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries","volume":"12","author":"Blumenfeld","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.gore.2024.101383_b0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bpobgyn.2011.11.008","article-title":"Chemotherapy and fertility","volume":"26","author":"Blumenfeld","year":"2012","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.gore.2024.101383_b0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.fertnstert.2007.02.010","article-title":"Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with hodgkin lymphoma","volume":"89","author":"Blumenfeld","year":"2008","journal-title":"Fertil. Steril."},{"issue":"7","key":"10.1016\/j.gore.2024.101383_b0075","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.1997.15.7.2636","article-title":"EMA\/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients","volume":"15","author":"Bower","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.gore.2024.101383_b0080","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.1999.17.9.2670","article-title":"Outcome and reproductive function after chemotherapy for ovarian dysgerminoma","volume":"17","author":"Brewer","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2024.101383_b0085","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1210\/jc.2010-2776","article-title":"Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women","volume":"96","author":"Broer","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"23","key":"10.1016\/j.gore.2024.101383_b0090","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes","volume":"53","author":"Chang","year":"1993","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.gore.2024.101383_b0095","first-page":"CD008018","article-title":"Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women","volume":"3","author":"Chen","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0100","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.3802\/jgo.2023.34.e12","article-title":"Fertility and prognosis assessment between bleomycin\/etoposide\/cisplatin and paclitaxel\/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study","volume":"34","author":"Chu","year":"2023","journal-title":"J. Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0105","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/IGC.0000000000001175","article-title":"Reproductive outcomes after gestational trophoblastic neoplasia. a comparison between single-agent and multiagent chemotherapy: retrospective analysis from the MITO-9 group","volume":"28","author":"Cioffi","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.gore.2024.101383_b0110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jama.2011.991","article-title":"Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial","volume":"306","author":"Del Mastro","year":"2011","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.gore.2024.101383_b0115","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/humupd\/dmt062","article-title":"The physiology and clinical utility of anti-Mullerian hormone in women","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum. Reprod. Update"},{"issue":"4","key":"10.1016\/j.gore.2024.101383_b0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/OGX.0b013e318224e97b","article-title":"The effects of chemotherapy and radiotherapy on fertility in premenopausal women","volume":"66","author":"Fleischer","year":"2011","journal-title":"Obstet. Gynecol. Surv."},{"issue":"8","key":"10.1016\/j.gore.2024.101383_b0125","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/cncr.21385","article-title":"Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane","volume":"104","author":"Fornier","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.gore.2024.101383_b0130","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/jc.2011-3032","article-title":"Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women","volume":"97","author":"Freeman","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.gore.2024.101383_b0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2021.04.038","article-title":"Chemotherapy-induced ovarian failure in young women with early breast cancer: prospective analysis of four randomised neoadjuvant\/adjuvant breast cancer trials","volume":"152","author":"Furlanetto","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"19","key":"10.1016\/j.gore.2024.101383_b0140","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1200\/JCO.2006.08.4590","article-title":"Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a gynecologic oncology group study","volume":"25","author":"Gershenson","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1743-7563.2007.00089.x","article-title":"Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy","volume":"3","author":"Gilani","year":"2007","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2024.101383_b0150","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","article-title":"Etoposide: four decades of development of a topoisomerase II inhibitor","volume":"34","author":"Hande","year":"1998","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.gore.2024.101383_b0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.802","article-title":"Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy","volume":"25","author":"Hodgson","year":"2007","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2024.101383_b0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/molehr\/gay005","article-title":"Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice","volume":"24","author":"Horicks","year":"2018","journal-title":"Mol. Hum. Reprod."},{"issue":"1","key":"10.1016\/j.gore.2024.101383_b0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2008.05.033","article-title":"Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor","volume":"111","author":"Kang","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2024.101383_b0170","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1210\/en.2005-0700","article-title":"Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5","volume":"147","author":"Kitajima","year":"2006","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.gore.2024.101383_b0180","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","article-title":"Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer","volume":"39","author":"Koyama","year":"1977","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.gore.2024.101383_b0185","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","article-title":"GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial","volume":"28","author":"Leonard","year":"2017","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.gore.2024.101383_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8120577","article-title":"Anti-HER2\/neu antibody reduces chemotherapy-induced ovarian toxicity-from bench to bedside","volume":"8","author":"Levi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.gore.2024.101383_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114028","article-title":"Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function","volume":"157","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0200","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1097-0142(20000715)89:2<391::AID-CNCR26>3.0.CO;2-V","article-title":"Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases","volume":"89","author":"Low","year":"2000","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.gore.2024.101383_b0205","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/bloodadvances.2021005557","article-title":"Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine","volume":"7","author":"Machet","year":"2023","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.gore.2024.101383_b0210","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/gyno.1994.1221","article-title":"Menstrual and hormone patterns in women treated with high-dose cisplatin and bleomycin","volume":"54","author":"Maneschi","year":"1994","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0215","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/biolre\/ioac008","article-title":"Preserving oocytes in oncofertilitydagger","volume":"106","author":"McClam","year":"2022","journal-title":"Biol. Reprod."},{"issue":"1\u20132","key":"10.1016\/j.gore.2024.101383_b0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0303-7207(00)00365-8","article-title":"Reproduction post-chemotherapy in young cancer patients","volume":"169","author":"Meirow","year":"2000","journal-title":"Mol. Cell. Endocrinol."},{"issue":"10","key":"10.1016\/j.gore.2024.101383_b0225","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gore.2024.101383_b0230","doi-asserted-by":"crossref","first-page":"17058","DOI":"10.1038\/s41598-020-74087-9","article-title":"Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells","volume":"10","author":"Nakamura","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.gore.2024.101383_b0235","doi-asserted-by":"crossref","first-page":"11904","DOI":"10.1038\/s41598-022-16182-7","article-title":"Low anti-Mullerian hormone levels are associated with an increased risk of incident early-onset vasomotor symptoms among premenopausal women","volume":"12","author":"NamGoung","year":"2022","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.gore.2024.101383_b0240","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2024.101383_b0245","doi-asserted-by":"crossref","first-page":"478","DOI":"10.5468\/ogs.2014.57.6.478","article-title":"The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies","volume":"57","author":"Park","year":"2014","journal-title":"Obstet. Gynecol. Sci."},{"key":"10.1016\/j.gore.2024.101383_b0250","doi-asserted-by":"crossref","DOI":"10.1177\/1179558119864584","article-title":"Potential mechanisms of ovarian protection with gonadotropin-releasing hormone agonist in breast cancer patients: a review","volume":"13","author":"Poggio","year":"2019","journal-title":"Clin. Med. Insights Reprod. Health"},{"issue":"6","key":"10.1016\/j.gore.2024.101383_b0255","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.fertnstert.2020.09.134","article-title":"Testing and interpreting measures of ovarian reserve: a committee opinion","volume":"114","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2020","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.gore.2024.101383_b0260","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-015-3426-z","article-title":"Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)","volume":"151","author":"Ruddy","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.gore.2024.101383_b0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10147-019-01540-9","article-title":"The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia","volume":"25","author":"Sato","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2024.101383_b0270","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.gore.2024.101383_b0275","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/ijc.33403","article-title":"M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin\/cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia","volume":"148","author":"Singh","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"14","key":"10.1016\/j.gore.2024.101383_b0280","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jama.2017.14588","article-title":"Association between biomarkers of ovarian reserve and infertility among older women of reproductive age","volume":"318","author":"Steiner","year":"2017","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.gore.2024.101383_b0285","doi-asserted-by":"crossref","first-page":"385e381","DOI":"10.1016\/j.ajog.2018.07.021","article-title":"Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study","volume":"219","author":"Tamauchi","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.gore.2024.101383_b0290","doi-asserted-by":"crossref","first-page":"1025018","DOI":"10.3389\/fendo.2022.1025018","article-title":"The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: a review of current evidence","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0295","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/toxsci\/kfx047","article-title":"Doxorubicin has dose-dependent toxicity on mouse ovarian follicle development, hormone secretion, and oocyte maturation","volume":"157","author":"Xiao","year":"2017","journal-title":"Toxicol. Sci."},{"issue":"5","key":"10.1016\/j.gore.2024.101383_b0300","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41419-023-05859-0","article-title":"Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.gore.2024.101383_b0305","first-page":"768","article-title":"Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey","volume":"86","author":"Zimmermann","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924000626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924000626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T21:03:09Z","timestamp":1731704589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578924000626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":61,"alternative-id":["S2352578924000626"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2024.101383","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maximizing ovarian function and fertility following chemotherapy in premenopausal patients: Is there a role for ovarian suppression?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2024.101383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101383"}}